



4-10  
HP  
4-30-02  
NB

PATENT  
Customer Number: 22,852  
Attorney Docket No. 5394.0011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stewart COLE et al.

Application No.: 09/673,476

International Appln. PCT/IB99/00740

Filed: October 16, 2000

International Filing

Date: April 16, 1999

)  
)  
) Group Art Unit: 1634

)  
) Examiner: J. Souaya

RECEIVED  
APR 08 2002  
TECH CENTER 1600/2900

For: A METHOD FOR ISOLATING A POLYNUCLEOTIDE OF INTEREST FROM  
THE GENOME OF A MYCOBACTERIUM USING A BAC-BASED DNA  
LIBRARY, APPLICATION TO THE DETECTION OF MYCOBACTERIA

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES**

In response to the Communication dated March 7, 2002, requesting compliance with the Sequence Rules, 37 C.F.R. §§ 1.821-1.825, applicants submit the following amendments and remarks.

**IN THE ABSTRACT:**

Please insert the attached Abstract following the claims.

**IN THE DRAWINGS:**

Please amend the Figures as indicated on the attached Request for Approval of Drawing Changes submitted concurrently herewith. Specifically, applicants have requested permission to amend Figures 6 and 7 to include appropriate SEQ ID Nos.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

**IN THE SPECIFICATION:**

Please replace the specification, as filed, with the substitute specification filed concurrently.

In the substitute specification, after page 131, and before the claims, beginning on a new page, please insert the attached sequence listing.

**REMARKS**

Claims 1-50 are pending in this application.

**Abstract**

Applicants submit with this response an abstract on a separate sheet of paper, as required by 37 C.F.R. § 1.72(b).

**Substitute Specification**

Applicants submit with this response a substitute specification pursuant to 37 C.F.R. § 1.125(b) as well as a marked up copy of the specification showing where amendments were made. Pursuant to 37 C.F.R. § 1.125(b)(1), the substitute specification contains no new matter and was amended to add the appropriate SEQ ID Nos. and to correct typographical errors.

**Sequence Listing**

In a Communication dated March 7, 2002, the Office noted that this application failed to comply with the requirements of the sequence rules. Specifically, the Office noted that applicants were required to submit a copy of the Sequence Listing in

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

computer readable form, a paper copy of the sequence listing, as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same.

Applicants submit with this response a copy of the Sequence Listing in computer readable form, a paper copy of the sequence listing, an amendment directing its entry into the substitute specification, and the appropriate statement.

If there is any fee due in connection with the filing of this paper, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 4, 2002

By: 

Timothy B. Donaldson  
Reg. No. 43,592

Tel: (202) 408-4000  
Fax: (202) 408-4400  
Email: [timothy.donaldson@finnegan.com](mailto:timothy.donaldson@finnegan.com)

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)